Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

The evaluation of fingermarks given activity level propositions.

de Ronde A, Kokshoorn B, de Poot CJ, de Puit M.

Forensic Sci Int. 2019 Jul 30;302:109904. doi: 10.1016/j.forsciint.2019.109904. [Epub ahead of print]

2.

A study into fingermarks at activity level on pillowcases.

de Ronde A, van Aken M, de Puit M, de Poot C.

Forensic Sci Int. 2019 Feb;295:113-120. doi: 10.1016/j.forsciint.2018.11.027. Epub 2018 Dec 7.

PMID:
30579242
3.

A Novel Virus Causes Scale Drop Disease in Lates calcarifer.

de Groof A, Guelen L, Deijs M, van der Wal Y, Miyata M, Ng KS, van Grinsven L, Simmelink B, Biermann Y, Grisez L, van Lent J, de Ronde A, Chang SF, Schrier C, van der Hoek L.

PLoS Pathog. 2015 Aug 7;11(8):e1005074. doi: 10.1371/journal.ppat.1005074. eCollection 2015 Aug.

4.

HIV-1 autologous antibody neutralization associates with mother to child transmission.

Baan E, de Ronde A, Stax M, Sanders RW, Luchters S, Vyankandondera J, Lange JM, Pollakis G, Paxton WA.

PLoS One. 2013 Jul 17;8(7):e69274. doi: 10.1371/journal.pone.0069274. Print 2013.

5.

HIV type 1 mother-to-child transmission facilitated by distinctive glycosylation sites in the gp120 envelope glycoprotein.

Baan E, de Ronde A, Luchters S, Vyankandondera J, Lange JM, Pollakis G, Paxton WA.

AIDS Res Hum Retroviruses. 2012 Jul;28(7):715-24. doi: 10.1089/AID.2011.0023. Epub 2011 Oct 24.

PMID:
21916748
6.

Mitochondrial DNA decline in T cells of HIV-1 seroconverters may be dependent on immune activation.

Casula M, Vrisekoop N, Wit FW, de Baar MP, de Ronde A, Miedema F, Reiss P.

J Infect Dis. 2007 Aug 1;196(3):371-6. Epub 2007 Jun 15.

PMID:
17597451
7.

Adaptation of HIV-1 depends on the host-cell environment.

van Opijnen T, de Ronde A, Boerlijst MC, Berkhout B.

PLoS One. 2007 Mar 7;2(3):e271.

8.

Identification of alternative amino acid substitutions in drug-resistant variants of the HIV-1 reverse transcriptase.

Berkhout B, Back NK, de Ronde A, Jurriaans S, Bakker M, Parkin NT, van der Hoek L.

AIDS. 2006 Jul 13;20(11):1515-20.

PMID:
16847406
9.

Evolution of transmitted HIV-1 with drug-resistance mutations in the absence of therapy: effects on CD4+ T-cell count and HIV-1 RNA load.

Bezemer D, de Ronde A, Prins M, Porter K, Gifford R, Pillay D, Masquelier B, Fleury H, Dabis F, Back N, Jurriaans S, van der Hoek L; CASCADE collaboration.

Antivir Ther. 2006;11(2):173-8.

PMID:
16640098
10.
11.

Infection with HIV-1 induces a decrease in mtDNA.

Casula M, Bosboom-Dobbelaer I, Smolders K, Otto S, Bakker M, de Baar MP, Reiss P, de Ronde A.

J Infect Dis. 2005 May 1;191(9):1468-71. Epub 2005 Mar 25.

PMID:
15809905
12.

Aggressive HIV-1?

Berkhout B, de Ronde A, van der Hoek L.

Retrovirology. 2005 Feb 28;2:13.

13.

Increased multinucleoside drug resistance and decreased replicative capacity of a human immunodeficiency virus type 1 variant with an 8-amino-Acid insert in the reverse transcriptase.

van der Hoek L, Back N, Jebbink MF, de Ronde A, Bakker M, Jurriaans S, Reiss P, Parkin N, Berkhout B.

J Virol. 2005 Mar;79(6):3536-43.

14.

APOBEC3G versus reverse transcriptase in the generation of HIV-1 drug-resistance mutations.

Berkhout B, de Ronde A.

AIDS. 2004 Sep 3;18(13):1861-3. No abstract available.

PMID:
15316354
15.

Prevalence of lipoatrophy and mitochondrial DNA content of blood and subcutaneous fat in HIV-1-infected patients randomly allocated to zidovudine- or stavudine-based therapy.

van der Valk M, Casula M, Weverlingz GJ, van Kuijk K, van Eck-Smit B, Hulsebosch HJ, Nieuwkerk P, van Eeden A, Brinkman K, Lange J, de Ronde A, Reiss P.

Antivir Ther. 2004 Jun;9(3):385-93.

PMID:
15259901
16.

Changes in mitochondrial DNA copy number in blood cells from HIV-infected patients undergoing antiretroviral therapy.

de Mendoza C, de Ronde A, Smolders K, Blanco F, Garcia-Benayas T, de Baar M, Fernández-Casas P, González-Lahoz J, Soriano V.

AIDS Res Hum Retroviruses. 2004 Mar;20(3):271-3.

PMID:
15117449
18.

Efficient human immunodeficiency virus replication requires a fine-tuned level of transcription.

Marzio G, Vink M, Verhoef K, de Ronde A, Berkhout B.

J Virol. 2002 Mar;76(6):3084-8.

19.

Carrier rate of zidovudine-resistant HIV-1: the impact of failing therapy on transmission of resistant strains.

Goudsmit J, Weverling GJ, van der Hoek L, de Ronde A, Miedema F, Coutinho RA, Lange JM, Boerlijst MC.

AIDS. 2001 Nov 23;15(17):2293-301.

PMID:
11698703
20.

Potent antiretroviral therapy initiates normalization of hypergammaglobulinemia and a decline in HIV type 1-specific antibody responses.

Notermans DW, de Jong JJ, Goudsmit J, Bakker M, Roos MT, Nijholt L, Cremers J, Hellings JA, Danner SA, de Ronde A.

AIDS Res Hum Retroviruses. 2001 Jul 20;17(11):1003-8.

PMID:
11485617
21.

Single rapid real-time monitored isothermal RNA amplification assay for quantification of human immunodeficiency virus type 1 isolates from groups M, N, and O.

de Baar MP, van Dooren MW, de Rooij E, Bakker M, van Gemen B, Goudsmit J, de Ronde A.

J Clin Microbiol. 2001 Apr;39(4):1378-84.

22.

Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus.

de Ronde A, van Dooren M, van Der Hoek L, Bouwhuis D, de Rooij E, van Gemen B, de Boer R, Goudsmit J.

J Virol. 2001 Jan;75(2):595-602.

23.

Epidemiology of HIV-1 and emerging problems.

Lukashov VV, de Ronde A, de Jong JJ, Goudsmit J.

Int J Antimicrob Agents. 2000 Dec;16(4):463-6.

PMID:
11118859
24.

Genetic analysis reveals epidemiologic patterns in the spread of human immunodeficiency virus.

Kuiken C, Thakallapalli R, Esklid A, de Ronde A.

Am J Epidemiol. 2000 Nov 1;152(9):814-22.

PMID:
11085392
25.

Natural residues versus antiretroviral drug-selected mutations in HIV type 1 group O reverse transcriptase and protease related to virological drug failure in vivo.

de Baar MP, Janssens W, de Ronde A, Fransen K, Colebunders R, Kestens L, van der Groen G, Goudsmit J.

AIDS Res Hum Retroviruses. 2000 Sep 20;16(14):1385-94.

PMID:
11018858
26.

Subtype-specific sequence variation of the HIV type 1 long terminal repeat and primer-binding site.

De Baar MP, De Ronde A, Berkhout B, Cornelissen M, Van Der Horn KH, Van Der Schoot AM, De Wolf F, Lukashov VV, Goudsmit J.

AIDS Res Hum Retroviruses. 2000 Mar 20;16(5):499-504.

PMID:
10772536
27.

Infection by zidovudine-resistant HIV-1 compromises the virological response to stavudine in a drug-naive patient.

de Ronde A, van Dooren M, de Rooij E, van Gemen B, Lange J, Goudsmit J.

AIDS. 2000 Nov 10;14(16):2632-3. No abstract available.

PMID:
11101087
28.

Envelope gene sequences encoding variable regions 3 and 4 are involved in macrophage tropism of feline immunodeficiency virus.

Vahlenkamp TW, de Ronde A, Schuurman NN, van Vliet AL, van Drunen J, Horzinek MC, Egberink HF.

J Gen Virol. 1999 Oct;80 ( Pt 10):2639-46.

PMID:
10573157
29.

The feline immunodeficiency virus envelope protein precursor: functional analysis of a leader deletion mutant.

Vahlenkamp TW, de Ronde A, Rottier PJ, Horzinek MC, Egberink HF, Verschoor EJ.

Vet Microbiol. 1999 Sep 1;69(1-2):115-6. No abstract available.

PMID:
10515280
30.

Design and evaluation of a human immunodeficiency virus type 1 RNA assay using nucleic acid sequence-based amplification technology able to quantify both group M and O viruses by using the long terminal repeat as target.

de Baar MP, van der Schoot AM, Goudsmit J, Jacobs F, Ehren R, van der Horn KH, Oudshoorn P, de Wolf F, de Ronde A.

J Clin Microbiol. 1999 Jun;37(6):1813-8.

31.

Detection of human immunodeficiency virus type 1 nucleocapsid protein p7 in vitro and in vivo.

de Baar MP, van der Horn KH, Goudsmit J, de Ronde A, de Wolf F.

J Clin Microbiol. 1999 Jan;37(1):63-7.

32.

Feline immunodeficiency virus subunit vaccines that induce virus neutralising antibodies but no protection against challenge infection.

Huisman W, Karlas JA, Siebelink KH, Huisman RC, de Ronde A, Francis MJ, Rimmelzwaan GF, Osterhaus AD.

Vaccine. 1998 Jan-Feb;16(2-3):181-7.

PMID:
9607028
33.

Salmonella typhimurium aroA recombinants and immune-stimulating complexes as vaccine candidates for feline immunodeficiency virus.

Tijhaar EJ, Huisman W, Huisman RC, Siebelink KH, Karlas JA, de Ronde A, van Herwijnen R, Mooi FR, Osterhaus AD.

J Gen Virol. 1997 Dec;78 ( Pt 12):3265-75.

PMID:
9400977
34.

A single amino acid substitution in the transmembrane envelope glycoprotein of feline immunodeficiency virus alters cellular tropism.

Vahlenkamp TW, Verschoor EJ, Schuurman NN, van Vliet AL, Horzinek MC, Egberink HF, de Ronde A.

J Virol. 1997 Sep;71(9):7132-5.

36.

[Quantification of feline immunodeficiency virus (FIV) RNA in the plasma of infected cats].

Vahlenkamp TW, De Ronde A, Horzinek MC, Egberink HF.

Berl Munch Tierarztl Wochenschr. 1996 Aug;109(8):265-9. German.

PMID:
9005834
38.

[Zidovudine-resistant HIV strains in intravenous drug users and homosexual men in Amsterdam].

de Ronde A, de Rooij ER, Coutinho RA, Goudsmit J.

Ned Tijdschr Geneeskd. 1996 Apr 27;140(17):932-4. Dutch.

PMID:
8676973
39.

Suppression of virus burden by immunization with feline immunodeficiency virus Env protein.

Hosie MJ, Dunsford TH, de Ronde A, Willett BJ, Cannon CA, Neil JC, Jarrett O.

Vaccine. 1996 Apr;14(5):405-11.

PMID:
8735552
40.

Evaluation of subunit vaccines against feline immunodeficiency virus infection.

Verschoor EJ, Willemse MJ, Stam JG, van Vliet AL, Pouwels H, Chalmers SK, Horzinek MC, Sondermeijer PJ, Hesselink W, de Ronde A.

Vaccine. 1996 Mar;14(4):285-9.

PMID:
8744554
41.

First case of new infection with zidovudine-resistant HIV-1 among prospectively studied intravenous drug users and homosexual men in Amsterdam, The Netherlands.

de Ronde A, Schuurman R, Goudsmit J, van den Hoek A, Boucher C.

AIDS. 1996 Feb;10(2):231-2. No abstract available.

PMID:
8838715
42.

A single mutation within the V3 envelope neutralization domain of feline immunodeficiency virus determines its tropism for CRFK cells.

Verschoor EJ, Boven LA, Blaak H, van Vliet AL, Horzinek MC, de Ronde A.

J Virol. 1995 Aug;69(8):4752-7.

43.

Enhancement of feline immunodeficiency virus infection after immunization with envelope glycoprotein subunit vaccines.

Siebelink KH, Tijhaar E, Huisman RC, Huisman W, de Ronde A, Darby IH, Francis MJ, Rimmelzwaan GF, Osterhaus AD.

J Virol. 1995 Jun;69(6):3704-11.

44.

Vaccination against feline immunodeficiency virus using fixed infected cells.

Verschoor EJ, van Vliet AL, Egberink HF, Hesselink W, van Alphen WE, Joosten I, Boog CJ, Horzinek MC, de Ronde A.

Vet Immunol Immunopathol. 1995 May;46(1-2):139-49.

PMID:
7618254
45.

Competitive reverse transcription-polymerase chain reaction for quantitation of feline immunodeficiency virus.

Vahlenkamp TW, Egberink HF, van Eijk MJ, Slotboom-Kamphorst AM, Verschoor EJ, Horzinek MC, de Ronde A.

J Virol Methods. 1995 Apr;52(3):335-46.

PMID:
7601907
46.

(R)-9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine is a potent inhibitor of feline immunodeficiency virus infection.

Vahlenkamp TW, De Ronde A, Balzarini J, Naesens L, De Clercq E, van Eijk MJ, Horzinek MC, Egberink HF.

Antimicrob Agents Chemother. 1995 Mar;39(3):746-9.

47.

Increased number of single-LTR HIV-1 DNA junctions correlates with HIV-1 antigen expression and CD4+ cell decline in vivo.

Jurriaans S, de Ronde A, Dekker J, Cornelissen M, Goudsmit J.

J Med Virol. 1995 Jan;45(1):91-8.

PMID:
7714497
48.

Monoclonal antibodies to immunodominant and neutralizing domains of the envelope surface protein of feline immunodeficiency virus.

Egberink H, Keldermans L, Schuurman N, Stam J, Hesselink W, van Vliet A, Verschoor E, Horzinek M, de Ronde A.

J Gen Virol. 1994 Apr;75 ( Pt 4):889-93.

PMID:
7512121
49.

Antibody response in cats to the envelope proteins of feline immunodeficiency virus: identification of an immunodominant neutralization domain.

de Ronde A, Stam JG, Boers P, Langedijk H, Meloen R, Hesselink W, Keldermans LC, van Vliet A, Verschoor EJ, Horzinek MC, et al.

Virology. 1994 Jan;198(1):257-64.

PMID:
8259661
50.

Expression of feline immunodeficiency virus gag and env precursor proteins in Spodoptera frugiperda cells and their use in immunodiagnosis.

Verschoor EJ, van Vliet AL, Egberink HF, Hesselink W, Horzinek MC, de Ronde A.

J Clin Microbiol. 1993 Sep;31(9):2350-5.

Supplemental Content

Loading ...
Support Center